Published June 9, 2026 | Cardiology Clinical Update | Guideline Summary
Background: What Is CKM Syndrome?
Cardiovascular-Kidney-Metabolic (CKM) syndrome is formally defined as a systemic disorder arising from pathophysiological interactions among metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multiorgan dysfunction and a high rate of adverse cardiovascular outcomes.
The newly released 2026 AHA/ACC/ADA/ASN guideline — published simultaneously in JACC and Circulation — replaces the 2013 obesity guideline and represents the first unified framework integrating obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease into a single clinical staging system.
A striking statistic underscores the urgency: 90–95% of U.S. adults currently fall into CKM stage 1 through 4, making this framework applicable to nearly every patient encountered in clinical practice.
The CKM Staging System: A Practical Framework
The guideline formalizes a five-stage CKM classification (stages 0–4) that reflects progressive pathophysiology, escalating cardiovascular risk, and guides therapeutic intensity.
| Stage | Definition | Key Diagnostic Criteria | Management Focus |
|---|---|---|---|
| Stage 0 | No CKM risk factors | Normal BMI, normoglycemia, normotension, normal lipids, no CKD/CVD | Primordial prevention |
| Stage 1 | Excess or dysfunctional adiposity | BMI ≥25 kg/m² or waist ≥88/102 cm (F/M); prediabetes (FBG 100–125 or HbA1c 5.7–6.4%) | Lifestyle + weight loss ≥5–10% |
| Stage 2 | Metabolic risk factors, CKD, or both | HTN, hypertriglyceridemia, MetS, T2D, and/or moderate–high-risk CKD (KDIGO) | Cardioprotective/kidney-protective pharmacotherapy |
| Stage 3 | Subclinical CVD with CKM overlap | CAC ≥100, Pre-HF (elevated NT-proBNP/troponin/echo), very high-risk CKD, or 10-yr CVD risk ≥20% | Intensified therapy; risk equivalent of clinical CVD |
| Stage 4a/4b | Clinical CVD + CKM factors | CHD, HF, stroke, PAD, or AFib with CKM comorbidities; 4b = kidney failure (eGFR <15) | GDMT optimization across all CKM domains |
Risk Quantification: The PREVENT Equations
The guideline mandates use of the PREVENT equations (Predicting Risk of Cardiovascular Disease EVENTs) — replacing the older Pooled Cohort Equations — to estimate 10-year and 30-year risk for ASCVD, heart failure, and total CVD in all individuals at CKM stages 0–3.
A predicted 10-year CVD risk ≥20% qualifies as a CKM stage 3 risk equivalent, and a threshold of ≥7.5% guides prioritization of pharmacotherapies — a critical anchor for clinical decision-making.
Risk enhancers — including chronic inflammatory conditions, adverse pregnancy outcomes, family history of diabetes or kidney failure, and elevated biomarkers — can further refine staging and support shared decision-making when 10-year risk is borderline.
Key Pharmacotherapy Recommendations
SGLT2 inhibitors and GLP-1–based therapies emerge as the cornerstone cardioprotective antihyperglycemic agents across nearly every CKM phenotype, with selection driven by coexisting comorbidities.
| Clinical Scenario | First-Line Agents | Add-On If Needed |
|---|---|---|
| T2D + CVD or high CVD risk | SGLT2i and/or GLP-1–based therapy | Metformin if HbA1c ≥0.5–1% above goal |
| CKD + T2D or albuminuria | RASi + SGLT2i (first-line) | Nonsteroidal MRA (finerenone) or GLP-1 RA if albuminuria persists |
| HFrEF + CKM | Quadruple therapy: ARNI/ACEi/ARB + beta-blocker + steroidal MRA + SGLT2i | Address obesity, T2D, CKD separately |
| HFpEF/HFmrEF + CKM | SGLT2i (first-line GDMT) | GLP-1–based therapy (obesity/CKM risk factors); nonsteroidal MRA (T2D + CKD) |
| Obesity alone (CKM stage 1), BMI ≥27 | GLP-1–based therapy + structured lifestyle | MBS if inadequate response; non-GLP-1 agents as alternative |
| ASCVD + obesity | Lifestyle + GLP-1–based therapy (reduces MACE/CV death) | Integrated weight management team; consider MBS |
Obesity Management: A Central Pillar
Lifestyle modification — targeting a caloric deficit of 500–750 kcal/day with ≥150 minutes/week of moderately vigorous aerobic activity — remains first-line, with a target weight loss of at least 5–10% of baseline body weight.
GLP-1–based pharmacotherapy (liraglutide, semaglutide, tirzepatide) achieves 5–21% placebo-corrected weight loss with additional benefits on BP, triglycerides, and glycemia; tirzepatide was shown superior to semaglutide in the SURMOUNT-5 trial for overall weight loss.
Metabolic and bariatric surgery (MBS) — comprising Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy — is cost-effective (ICER consistently <$120,000/QALY) and is indicated for patients with BMI ≥35 kg/m² who fail lifestyle ± pharmacotherapy, or for those with T2D and BMI ≥30 kg/m².
Critically, nonjudgmental weight loss counseling is a Class I recommendation — patients who experience weight stigma in clinical encounters are less likely to engage with care and have worse outcomes.
CKD Assessment: Both eGFR and UACR Are Required
The guideline is explicit: assessment of both eGFR and urine albumin-to-creatinine ratio (UACR) is required to characterize CKD — eGFR alone is insufficient and will miss patients with albuminuric CKD who qualify for kidney-protective therapy.
The KDIGO heat map is incorporated directly into CKM staging: stages G3a with A3, G3b with A2–A3, or G4–G5 constitute "very high-risk CKD" — a CKM stage 3 risk equivalent warranting intensified therapy even in the absence of clinical CVD.
Interdisciplinary Care and the CKM Coordination Point Person
For patients with ≥2 overlapping CKM conditions (T2D, CKD, CVD), a Class I, Level B-R recommendation calls for use of interdisciplinary care teams with a designated CKM coordination point person to harmonize GDMT implementation, lifestyle support, and medication management.
This model operationalizes in two formats: value-based care (cross-specialty teams with shared protocols) and volume-based care (subspecialty referrals with navigator support) — both available virtually or in-person, with flexibility for resource-limited settings.
Social Determinants of Health: A Formal Part of CKM Care
Social determinants of health (SDOH) — including food insecurity, housing instability, and socioeconomic barriers — are now formally integrated into CKM staging assessments, with a Class I recommendation to routinely screen and mitigate adverse SDOH as part of holistic care.
Community health workers, social workers, and patient navigators are explicitly listed as members of the CKM interdisciplinary team, reflecting the evidence that addressing SDOH improves access to therapies and reduces 30-day readmissions.
Additional High-Yield Points
Metabolic dysfunction–associated steatotic liver disease (MASLD) — the updated term replacing NAFLD — warrants GLP-1 RA therapy in patients with fibrotic MASLD and T2D, given the high risk of progression and cardiovascular burden.
Obstructive sleep apnea (OSA) should be screened for in select patients, as it is increasingly recognized as both a contributor to and complication of CKM syndrome — it does not interfere with weight loss success in lifestyle intervention trials.
Women with a history of gestational diabetes mellitus (GDM) face a 35–60% lifetime risk of T2D and should receive a 75-g oral glucose tolerance test 4–12 weeks postpartum, with metformin or lifestyle modification if prediabetes is confirmed — now a Class I recommendation.
LDL-C management in CKM syndrome is addressed in the companion 2026 Dyslipidemia Guideline; clinicians should cross-reference risk enhancers that overlap between the two frameworks.
Case Resolution
Returning to our patient: with T2D, CKD (eGFR 52, UACR 180 mg/g = moderate–high-risk CKD), and a 10-year PREVENT CVD risk of 23%, he is classified as CKM stage 3 (risk equivalent of subclinical CVD).
Guideline-directed management includes: (1) add an SGLT2 inhibitor to his current RASi for CKD and cardiovascular protection; (2) initiate a GLP-1–based therapy given obesity, T2D, and elevated CVD risk; (3) target ≥10% weight loss; (4) screen UACR at follow-up — if albuminuria persists, add finerenone; (5) refer to an interdisciplinary CKM team; and (6) screen for SDOH barriers to medication access.
References
- Ndumele CE, et al. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of CKM Syndrome. J Am Coll Cardiol. 2026;87(22S):e1889–e2007.
- Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory from the AHA. Circulation. 2023;148:1606–1635.
- Kidney Disease: Improving Global Outcomes (KDIGO). CKD Evaluation and Management Guidelines 2024. KDIGO.org.
- American Heart Association. PREVENT Risk Calculator. Professional.heart.org.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). N Engl J Med. 2023;389:2221–2232.
- Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced). N Engl J Med. 2020;383:1413–1424.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.